Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2152)
All Articles published online
|
Apr 28, 2008 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i16/2544.htm |
| Number | Citing Articles |
| 1 |
Ian C Lawrance. Microbiota and management of inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2012; 27(7): 1137 doi: 10.1111/j.1440-1746.2012.07163.x
|
| 2 |
Ian Craig Lawrance. Biomarkers in Inflammatory Bowel Diseases. 2019; : 141 doi: 10.1007/978-3-030-11446-6_12
|
| 3 |
Ian C Lawrance, Graham L Radford‐Smith, Peter A Bampton, Jane M Andrews, Pok‐Kern Tan, Anthony Croft, Richard B Gearry, Timothy H J Florin. Serious infections in patients with inflammatory bowel disease receiving anti‐tumor‐necrosis‐factor‐alpha therapy: An Australian and New Zealand experience. Journal of Gastroenterology and Hepatology 2010; 25(11): 1732 doi: 10.1111/j.1440-1746.2010.06407.x
|
| 4 |
Ágnes Milassin, Anna Fábián, Tamás Molnár. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therapeutic Advances in Gastroenterology 2019; 12: 175628481984274 doi: 10.1177/1756284819842748
|
| 5 |
Nabeel Khan, Dhruvan Patel, Tyler Pernes, Manthankumar Patel, Chinmay Trivedi, Elina Medvedeva, Dawei Xie, Yu-Xiao Yang. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2021; 3(2) doi: 10.1093/crocol/otab022
|
| 6 |
J. Gapasin, D. R. Van Langenberg, G. Holtmann, D. J. Hetzel, J. M. Andrews. Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines‐based audit. Internal Medicine Journal 2012; 42(5) doi: 10.1111/j.1445-5994.2010.02328.x
|
| 7 |
Ian Craig Lawrance. Novel topical therapies for distal colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics 2010; 1(5): 87-93 doi: 10.4292/wjgpt.v1.i5.87
|
| 8 |
Ahmed Al-Darmaki, James Hubbard, Cynthia H. Seow, Yvette Leung, Kerri Novak, Abdel Aziz Shaheen, Remo Panaccione, Gilaad G. Kaplan. Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis. Inflammatory Bowel Diseases 2017; 23(8): 1272 doi: 10.1097/MIB.0000000000001211
|
| 9 |
Ajit Sood, Vandana Midha, Suresh Sharma, Neena Sood, Manu Bansal, Amandeep Thara, Pankaj Khanna. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian Journal of Gastroenterology 2014; 33(1): 31 doi: 10.1007/s12664-013-0372-8
|
| 10 |
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo, Sami Hoque. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment 2016; 20(39): 1 doi: 10.3310/hta20390
|
| 11 |
Mats Sjöberg, Andrea Walch, Mina Meshkat, Anders Gustavsson, Gunnar Järnerot, Harald Vogelsang, Erik Hertervig, Gottfried Novacek, Ingalill Friis-Liby, Lars Blomquist, Sieglinde Angelberger, Per Karlen, Christer Grännö, Mogens Vilien, Magnus Ström, Hans Verbaan, Per M. Hellström, Clemens Dejaco, Anders Magnuson, Jonas Halfvarson, Walter Reinisch, Curt Tysk. Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study. Inflammatory Bowel Diseases 2012; 18(2): 212 doi: 10.1002/ibd.21680
|
| 12 |
Ane Søgaard Teisner, Mark A Ainsworth, Jørn Brynskov. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience. Scandinavian Journal of Gastroenterology 2010; 45(12): 1457 doi: 10.3109/00365521.2010.510572
|
| 13 |
A. Croft, A. Walsh, J. Doecke, R. Cooley, M. Howlett, G. Radford-Smith. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Alimentary Pharmacology & Therapeutics 2013; 38(3): 294 doi: 10.1111/apt.12375
|
| 14 |
G. R. Lichtenstein, G. L. Gordon, S. Zakko, U. Murthy, S. Sedghi, R. Pruitt, K. Merchant, A. Shaw, E. Bortey, W. P. Forbes. Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial. Alimentary Pharmacology & Therapeutics 2010; 32(8): 990 doi: 10.1111/j.1365-2036.2010.04438.x
|
| 15 |
K. Kato, T. Ohkusa, S. Terao, T. Chiba, K. Murakami, A. Yanaka, T. Uehara, Y. Ishii, M. Soma, H. Tajiri. Adjunct antibiotic combination therapy for steroid‐refractory or ‐dependent ulcerative colitis: an open‐label multicentre study. Alimentary Pharmacology & Therapeutics 2014; 39(9): 949 doi: 10.1111/apt.12688
|
| 16 |
William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology 2009; 137(4): 1250 doi: 10.1053/j.gastro.2009.06.061
|
| 17 |
Manuel Barreiro-de Acosta, Aurelio Lorenzo, Jose Mera, J. Enrique Dominguez-Muñoz. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. Journal of Crohn's and Colitis 2009; 3(4): 271 doi: 10.1016/j.crohns.2009.06.003
|
| 18 |
I. C. Lawrance. The importance of validating proposed genetic profiles in IBD. Journal of Internal Medicine 2014; 275(5): 481 doi: 10.1111/joim.12180
|
| 19 |
Ian Craig Lawrance. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Expert Opinion on Investigational Drugs 2012; 21(7): 975 doi: 10.1517/13543784.2012.690030
|
| 20 |
Matthew W. Trinder, Ian C. Lawrance. Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting. Journal of Gastroenterology and Hepatology 2009; 24(7): 1252 doi: 10.1111/j.1440-1746.2009.05786.x
|
| 21 |
Ian Craig Lawrance. Topical agents for idiopathic distal colitis and proctitis. Journal of Gastroenterology and Hepatology 2011; 26(1): 36 doi: 10.1111/j.1440-1746.2010.06497.x
|